Get the app
US › Healthcare

Molecular Partners AG ADR (MOLN)

US · Healthcare · Biotechnology

$3.920.00%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-13.5M
EPS
$-0.44
EPS estimate
$-0.45

EPS came in at -0.44 against a street estimate of -0.45 — a beat of 2.2%.

Key statistics

Market cap
$160.9M
Forward P/E
1.7
P/B
2.21
Book value
$1.90
EPS (TTM)
$-1.67
52-week high
$5.36
52-week low
$3.53
50-day MA
$4.15
200-day MA
$4.24
Beta
0.69

Analyst view

Analysts rate Molecular Partners AG ADR a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $10.59.

Shareholding

Institutions
9.38%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC5.94%
Bvf Inc3.62%
Morgan Stanley - Brokerage Accounts0.00%
EverSource Wealth Advisors, LLC0.00%
SmartHarvest Portfolios, LLC0.00%
UBS Group AG0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Molecular Partners AG ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.